Tremelimumab

Medical uses

Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma.

Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase positive mutations.

Mechanism of action

Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells.

Like ipilimumab, tremelimumab is antibody that binds to the protein CTLA-4, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.

Unlike Ipilimumab (another fully human anti-CTLA-4 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.

History

Previously in development by Pfizer, it is in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca.

Clinical trials

Melanoma

Phase I and II clinical studies in metastatic melanoma showed some responses. However, based on early interim analysis of phase III data, Pfizer designated tremelimumab as a failure and terminated the trial in April 2008.

However, within a year, the survival curves showed separation of the treatment and control groups.

Mesothelioma

Although it was designated in April 2015 as orphan drug status in mesothelioma, tremelimumab failed to improve lifespan in the phase IIb DETERMINE trial, which assessed the drug as a second or third-line treatment for unresectable malignant mesothelioma.

Non-small cell lung cancer

In a phase III trial, AstraZeneca paired tremelimumab with a PD-L1 inhibitor, durvalumab, for the first-line treatment of non-small cell lung cancer. The trial was conducted across 17 countries, and in July 2017, AstraZeneca announced that it had failed to meet its primary endpoint of progression-free survival.

Society and culture

Legal status

On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Imjudo, intended for the treatment of hepatocellular carcinoma. The applicant for this medicinal product is AstraZeneca AB. Tremelimumab was approved for medical use in the European Union in February 2023.

Names

Tremelimumab is the international nonproprietary name (INN).

References

References

1. (29 June 2023). "Imjudo".
2. (28 July 2023). "Imjudo (AstraZeneca Pty Ltd)".
3. "AusPAR: Imjudo".
4. (26 October 2023). "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]".
5. (3 January 2024). "Summary Basis of Decision (SBD) for Imjudo".
6. (23 October 2023). "Details for: Imjudo".
7. (10 November 2022). "Imjudo- tremelimumab injection, solution".
8. (9 December 2022). "Imjudo EPAR".
9. (4 November 2022). "Drug Approval Package: Imjudo".
10. (26 October 2022). "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer".
11. (10 November 2022). "FDA approves tremelimumab in combination with durvalumab and platinum-".
12. (June 2012). "Tumor immunotherapy directed at PD-1". The New England Journal of Medicine.
13. "Tremelimumab".
14. (October 2008). "Gateways to clinical trials". Methods Find Exp Clin Pharmacol.
15. Poust J. (December 2008). "Targeting metastatic melanoma". Am J Health Syst Pharm.
16. (1 April 2008). "Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma". Pfizer.com.
17. [https://www.azimmuno-oncology.com/ctla-4-inhibition#Tremelimumab Mechanism of Pathway: CTLA-4 Inhibition]{{Dead link. (April 2019)
18. (June 2006). "Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma". Cancer.
19. (February 2013). "Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma". Journal of Clinical Oncology.
20. (May 2010). "Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma". Journal of Clinical Oncology.
21. (17 April 2015). "FDA Grants AstraZeneca's Tremelimumab Orphan Drug Status for Mesothelioma". Mesothelioma Cancer Alliance.
22. (29 February 2016). "Tremelimumab Fails Mesothelioma Drug Trial". FDA News Alert.
23. (1 March 2016). "AZ' tremelimumab fails in mesothelioma trial". PharmaTimes.
24. (27 July 2017). "AstraZeneca's immuno-oncology combo fails crucial Mystic trial in lung cancer". FierceBiotech.
25. (27 July 2017). "AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer". AstraZeneca.
26. (15 December 2022). "Imjudo: Pending EC decision".
27. (23 February 2023). "Imjudo Product information".
28. (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information.